ArticleGeneral thoracic and cardiovascular surgery2026
Outcomes of mitral valve surgery for nonischemic ventricular functional mitral regurgitation.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the outcomes of mitral valve surgery for nonischemic ventricular functional mitral regurgitation (left ventricular ejection fraction ≤ 40%).
methodsStudy subjects were identified from the Japan Cardiovascular Surgery Database. Early and late mortality were assessed relative to established risk models. The extent of postoperative left ventricular reverse remodeling was also investigated.
resultsA total of 131 patients were categorized into four groups: mitral valve repair alone (n = 25), mitral valve repair with subvalvular procedures (n = 18), mitral valve replacement alone (n = 81), and mitral valve replacement with subvalvular procedures (n = 7). Estimated operative mortality was 5.9%, 5.5%, 12.8%, and 11.6% for each group, while observed mortality was 8.0%, 16.7%, 11.1%, and 0% (corresponding to observed-to-estimated ratio of 1.36, 3.03, 0.87, and 0.00, respectively). Observed 2-year mortality rates were 19.5%, 25.6%, 24.5%, and 16.7% for each group, and were lower than the corresponding estimated mortality across all groups. Subvalvular procedures were associated with greater postoperative left ventricular reverse remodeling. Furthermore, papillary muscle suspension was associated with lower operative mortality (observed-to-estimated ratio = 0.77 vs. 4.03 without suspension), whereas papillary muscle approximation was not.
conclusionsGiven the favorable risk-adjusted outcomes and postoperative reverse remodeling, mitral valve surgery, particularly when combined with a subvalvular procedure, remains a feasible option for patients with nonischemic VFMR even in the era of catheter-based treatment.
Indexed as
Identifiers
42734733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.